why choose us

First received: September 16, 2022

Clinical Trial: Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Melanoma

Study Type: Observational


Official Title: Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

Brief Summary: This is a non-randomized experimental biomarker study evaluating ctDNA levels in patients with stage IIB/C and stage IIIB/C/D melanoma skin cancer pre and post-surgeryStudy participants will complete a ctDNA test within 4 weeks of their planned surgical resection of their melanoma. Within 4 weeks post-surgery another ctDNA test will be completed. During these time points stool samples and diet questionnaires will be collected for biospecimen banking.

Read more